Author: Editor
Eli Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023. Mike Blake | ReutersEli Lilly on Tuesday said its daily weight loss pill helped patients with obesity and Type 2 diabetes shed weight in a late-stage trial, meeting the study’s main goal and clearing the way for the company to file for approval of the drug globally. The treatment is inching closer to becoming a new, needle-free alternative in the highly lucrative market for weight loss and diabetes drugs called GLP-1s. More convenient pills could boost supply for the treatments and make them easier to access than…
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here